Powered by OpenAIRE graph
Found an issue? Give us feedback
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ Archivio istituziona...arrow_drop_down
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
Neuropsychiatric Disease and Treatment
Article . 2025 . Peer-reviewed
License: CC BY NC
Data sources: Crossref
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
PubMed Central
Article . 2025
License: CC BY NC
Data sources: PubMed Central
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
Dove Medical Press
Article . 2025 . Peer-reviewed
Data sources: Dove Medical Press
versions View all 4 versions
addClaim

Cenobamate for Difficult-to-Treat Epilepsy – Selected Case Vignettes

Authors: Flavio Villani; Fedele Dono; Francesca Operto; Pietro Pignatta; Monica Puligheddu; Carlotta Stipa; Tiziano Zanoni;

Cenobamate for Difficult-to-Treat Epilepsy – Selected Case Vignettes

Abstract

Epilepsy affects millions worldwide, presenting unique challenges in specific populations such as the elderly, children, and patients with comorbidities or drug-resistant forms. Tailored approaches addressing unmet needs in these subgroups are critical to improving outcomes.This research uniquely integrates real-world evidence and detailed case vignettes from the EPI CONNECT project to evaluate the role of cenobamate in managing these complex cases, providing practical insights beyond traditional clinical trials. The article explores the potential of cenobamate, a novel antiseizure medication with dual mechanisms of action, in improving seizure control, simplifying polytherapy, and enhancing tolerability across various subpopulations. Case-based narratives illustrate its practical use in challenging scenarios.Cenobamate offers important advantages for underserved epilepsy populations, including seizure improvement, polypharmacy reduction, and improved adherence and quality of life. This review seeks to bridge current clinical practice with ongoing research efforts, fostering improved personalized treatment approaches and advancing understanding of cenobamate's long-term role in managing difficult-to-treat epilepsy populations. It aims to provide practical guidance for clinicians and to highlight future research directions, encouraging ongoing investigation into long-term efficacy, safety, and personalized care strategies.

Country
Italy
Keywords

epilepsy management, Neuropsychiatric Disease and Treatment, Lennox-Gastaut syndrome, seizure control, vagus nerve stimulation, DEEs, cenobamate, Expert Opinion, developmental and epileptic encephalopathies, drug-resistant epilepsy, antiseizure medication, pharmacoresistance, cognitive comorbidities

  • BIP!
    Impact byBIP!
    selected citations
    These citations are derived from selected sources.
    This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    0
    popularity
    This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
    Average
    influence
    This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    Average
    impulse
    This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
    Average
Powered by OpenAIRE graph
Found an issue? Give us feedback
selected citations
These citations are derived from selected sources.
This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Citations provided by BIP!
popularity
This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
BIP!Popularity provided by BIP!
influence
This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Influence provided by BIP!
impulse
This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
BIP!Impulse provided by BIP!
0
Average
Average
Average
Green
gold